- Keywords > anti-cancer medicines
- Keywords > cancer and cancer therapeutics
- Keywords > global burden of diseases
- Keywords > pharmaceutical gaps
- Keywords > pharmaceutical innovation
- Keywords > pharmaceutical research - priorities
- Keywords > policy - priority issues
- Keywords > priority diseases
- Keywords > priority medicines
(2013; 62 pages)
When the original (2004) Background paper was written, malignant tumours were responsible for 12% of the nearly 56 million deaths worldwide from all causes and over 6 million died specifically from some type of malignant tumour. Indeed, cancer had emerged as a major public health problem in developing countries, matching its effect in industrialized nations. In the European Union (EU) at that time, lung cancer was the principal cause of death in men (25% of all male cancer deaths) followed by colorectal and prostate cancers. In women, the three major causes of death were breast cancer (16% of all female deaths), colorectal (12%) and lung cancer (9%).
At that time, there was a large and dynamic pipeline of products. Further, at that time, the distribution of therapeutics in clinical trials across cancer types seems to correlate with the incidence of those cancer types reasonably well, suggesting that the pharmaceutical industry is appropriately matching its resources to the size of the market. The European Union did not match the private or public funding levels of the United States with regard to cancer therapeutic research and development.